BioSyntech Inc.: New Chairman and Annual Meeting.Business Editors LAVAL, Quebec--(BUSINESS WIRE)--Aug. 29, 2002 Dr. Amine amine (əmēn`, ăm`ēn): see under amino group. amine Any of a class of nitrogen-containing organic compounds derived, either in principle or in practice, from ammonia (NH3). Selmani, Chief Executive Officer of Biosyntech Inc. (OCTBB: BSYI), is pleased to announce that the Board of Directors of the Company has appointed Mr. Serge Savard as its new Chairman. Mr. Savard, who has been a director of the Company since July, 2001, is a well known Montreal based businessman who is a senior partner with Thibault, Messier, Savard. Prior to 1993, Mr. Savard served in various capacities with the Montreal Canadiens Hockey Club, including as Vice President and General Manager. "We are pleased that Mr. Savard has accepted the office of Chairman", said Dr. Selmani. "Separating the functions of Chairman and Chief Executive Officer was one of our priorities from a corporate governance Corporate Governance The relationship between all the stakeholders in a company. This includes the shareholders, directors, and management of a company, as defined by the corporate charter, bylaws, formal policy, and rule of law. point of view and this added implication of Mr. Savard will enable the Company to benefit even more from his vast experience in the business world and his extensive contacts in the community." On the same occasion, Dr. Selmani announced that the annual meeting of shareholders of the Company will be held on December 4, 2002 at 3.00pm, in Montreal and that Mr. Jean-Yves Bourgeois' resignation from the Board of Directors had been accepted. About BioSyntech BioSyntech Inc. is an ISO (1) See ISO speed. (2) (International Organization for Standardization, Geneva, Switzerland, www.iso.ch) An organization that sets international standards, founded in 1946. The U.S. member body is ANSI. 9001:2000 certified, advanced biomaterials company specializing in tissue repair and in the delivery of therapeutic products. BioSyntech is composed of two operating divisions: tissue repair and therapeutic delivery. The Company's patented platform technology BST-Gel(TM), is a multifunctional injectable thermo-sensitive and self-forming hydrogel hy·dro·gel n. A colloidal gel in which the particles are dispersed in water. hydrogel a gel that contains water. hydrogel Wound care A polymer absorptive wound dressing. See Dressing. that can be used for tissue repair or for targeted delivery of therapeutic agents. These biomaterials are biocompatible biocompatible /bio·com·pat·i·ble/ (-kom-pat´i-b'l) being harmonious with life; not having toxic or injurious effects on biological function. , biodegradable, muco adhesive and provide significant advantages in specialized medical fields including, Oncology, Orthopedics, Rheumatology rheumatology /rheu·ma·tol·o·gy/ (-tol´ah-je) the branch of medicine dealing with rheumatic disorders, their causes, pathology, diagnosis, treatment, etc. rheu·ma·tol·o·gy n. , Reconstructive Surgery reconstructive surgery n. Plastic surgery. reconstructive surgery, n surgery to rebuild a structure for functional or esthetic reasons. , Tissue Engineering, Vaccines and many other therapeutic areas. For additional information, visit www.biosyntech.com. This press release contains certain "forward-looking" statements, as defined in the United States Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Potential risks and uncertainties include timeframes and expectations for completing clinical trial research, receiving positive results from the various clinical trials, submitting results to various regulatory authorities, receiving approval for products and successfully marketing products to potential customers. These risks and factors are detailed from time to time in the company's SEC filings |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion